期刊
INVESTIGATIONAL NEW DRUGS
卷 32, 期 5, 页码 1048-1052出版社
SPRINGER
DOI: 10.1007/s10637-014-0063-z
关键词
Prostate cancer; Pseudolymphoma; Generalized lymphadenopathy; CD20; CCR7; Rituximab
A role for CD20 antibodies in treating prostate cancer has not yet been established. We report a case of advanced prostate cancer presenting with generalized lymphadenopathy that expressed CCR7 and CD20. CCR7 expression in prostate cancer has been previously reported only once; the expression of CD20 has not been reported before. Rituximab therapy was initiated in this case and resulted in a significant biochemical response. This unique metastatic and biochemical pattern may signify a distinct subtype of prostate cancer that may be amenable to treatment with anti-CD20 antibodies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据